Artiva Biotherapeutics ARTV
NASDAQ ARTV
$6.83 +0.04 (+0.59%)
At close: Oct 2, 2026 · 4:00 PM EDT

Artiva Biotherapeutics (ARTV) Return on Sales [ROS] (2023 - 2024)

Updated

Artiva Biotherapeutics (ARTV) reported Return on Sales [ROS] of -26806.37% for Q4 2024, down 26297.01 percentage points from -509.36% a year earlier and down 24461.62 percentage points from the prior quarter.

Analysis

Artiva Biotherapeutics (ARTV) Return on Sales [ROS] (2023 - 2024) Analysis & Trends

For FY2024, Artiva Biotherapeutics posted Return on Sales [ROS] of -26805.58%, down 26714.00 percentage points from FY2023.

  • By year, Return on Sales [ROS] came in at -91.58% in FY2023.
  • Per Business Quant data, the three quarters before Q4 2024 came in at -2344.75% (Q3 2024), -108.83% (Q2 2024) and -5773.71% (Q1 2024).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Artiva Biotherapeutics 269.19 Mn 269.19 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -26,806.37%
Sep 30, 2024 -2,344.75%
Jun 30, 2024 -108.83%
Mar 31, 2024 -5,773.71%
Dec 31, 2023 -509.36%
Sep 30, 2023 40.56%
Jun 30, 2023 -338.12%
API Access

Artiva Biotherapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=ARTV&period=max&api_key=YOUR_API_KEY